TB-500 10mg – PharmaTech

TB-500 is commonly used as the designation for a synthetic peptide related to Thymosin Beta-4 (Tβ4). However, the terminology is inconsistent across the peptide industry: TB-500 may refer either to the N-acetylated seven-amino-acid fragment Ac-LKKTETQ corresponding to residues 17–23 of Tβ4, or, in some commercial contexts, to full-length synthetic Thymosin Beta-4. These are chemically distinct molecules with substantially different molecular weights.

For analytical accuracy, PharmaTech product specifications should identify the exact molecular form, sequence, molecular weight, and lot-specific analytical results.

The research described below focuses primarily on the TB-500 fragment Ac-LKKTETQ and the biological literature surrounding the Thymosin Beta-4 actin-binding region.

OVERVIEW

TB-500 is commonly used as the designation for a synthetic peptide related to Thymosin Beta-4 (Tβ4). However, the terminology is inconsistent across the peptide industry: TB-500 may refer either to the N-acetylated seven-amino-acid fragment Ac-LKKTETQ corresponding to residues 17–23 of Tβ4, or, in some commercial contexts, to full-length synthetic Thymosin Beta-4. These are chemically distinct molecules with substantially different molecular weights.

For analytical accuracy, PharmaTech product specifications should identify the exact molecular form, sequence, molecular weight, and lot-specific analytical results.

The research described below focuses primarily on the TB-500 fragment Ac-LKKTETQ and the biological literature surrounding the Thymosin Beta-4 actin-binding region.


MECHANISM OF ACTION

The TB-500 fragment corresponds to the region of Thymosin Beta-4 associated with actin binding. Actin is a central component of the cytoskeleton and plays an important role in cellular morphology, migration, adhesion, and tissue remodeling.

Research involving the Thymosin Beta-4 actin-binding motif has demonstrated biological activity associated with endothelial-cell migration and angiogenic processes. Experimental studies identified the seven-amino-acid actin-binding motif as an important region for these activities.

Principal Research Pathway

TB-500 / Tβ4-related signaling → actin dynamics → cytoskeletal organization → cellular migration & tissue-remodeling processes

Additional research involving full-length Tβ4 has investigated pathways associated with:

  • Actin polymerization
  • Cellular migration
  • Angiogenesis
  • Extracellular matrix remodeling
  • Fibroblast activity
  • Tissue regeneration

The extent to which these observations from full-length Tβ4 can be directly attributed to the short TB-500 fragment remains an important distinction in interpreting the scientific literature.


KEY BENEFITS

Cellular & Cytoskeletal Research

  • Actin-related signaling
  • Cytoskeletal organization
  • Cellular migration
  • Cell adhesion
  • Cellular remodeling

Tissue Biology

  • Tissue remodeling research
  • Extracellular matrix biology
  • Fibroblast activity
  • Regenerative biology
  • Wound-healing models

Angiogenesis Research

  • Endothelial-cell migration
  • Vascular remodeling
  • Vessel formation models
  • Angiogenic signaling

Musculoskeletal Research

  • Connective-tissue biology
  • Tendon and ligament research
  • Muscle tissue remodeling
  • Cellular responses to tissue injury

RESEARCH AREAS

Research Area Primary Focus
Actin Biology G-actin interaction and cytoskeletal regulation
Cell Migration Cellular movement and directional migration
Angiogenesis Endothelial migration and vascular remodeling
Tissue Remodeling Cellular and extracellular matrix processes
Wound-Healing Research Experimental tissue-repair models
Musculoskeletal Biology Muscle, tendon and connective-tissue research
Regenerative Biology Cellular responses associated with tissue remodeling
Cellular Signaling Cytoskeletal and migration-associated pathways

SCIENTIFIC EVIDENCE

The strongest mechanistic evidence relevant to TB-500 comes from research on Thymosin Beta-4 and its actin-binding region.

Experimental studies demonstrated that the seven-amino-acid actin-binding motif of Tβ4 can reproduce important angiogenic activity in experimental systems, including endothelial-cell migration and vessel-sprouting models.

Separate studies with full-length Tβ4 demonstrated stimulation of endothelial-cell migration and angiogenic responses in vitro and in vivo experimental models.

It is important scientifically to distinguish these findings from direct evidence for commercially designated TB-500. Much of the regenerative literature concerns full-length Thymosin Beta-4, rather than the isolated TB-500 fragment.

Therefore, PharmaTech’s scientific positioning should distinguish TB-500 fragment identity from the broader Thymosin Beta-4 research literature.


MOLECULAR PROFILE

TB-500 Fragment — Ac-LKKTETQ

Parameter Specification
Compound Name TB-500
Chemical Description N-acetylated Thymosin Beta-4 fragment
Parent Protein Thymosin Beta-4
Residues 17–23
Peptide Length 7 amino acids
Sequence Ac-LKKTETQ
Molecular Formula C₃₈H₆₈N₁₀O₁₄
Molecular Weight ~889.0 Da
CAS Number 885340-08-9
Structural Modification N-terminal acetylation
Molecular Class Synthetic heptapeptide

Current chemical references identify Ac-LKKTETQ as the seven-residue acetylated fragment corresponding to residues 17–23 of Thymosin Beta-4.

Peptide Sequence

Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln

Ac-LKKTETQ


THYMOSIN BETA-4 DISTINCTION

Because the name TB-500 is inconsistently used commercially, analytical identification is particularly important.

TB-500 Fragment

  • 7 amino acids
  • Ac-LKKTETQ
  • ~889 Da
  • Corresponds to residues 17–23 of Tβ4

Full-Length Thymosin Beta-4

  • 43 amino acids
  • ~4,963 Da
  • Full-length TMSB4X gene product
  • Contains the LKKTETQ actin-binding region

These molecules should not be treated as chemically identical simply because both are marketed under the TB-500 designation.


PHARMACOKINETIC & PHARMACODYNAMIC PROFILE

Pharmacodynamic Profile

The pharmacodynamic research associated with the TB-500/Tβ4 family centers on cytoskeletal and cellular processes involving:

  • Actin interaction
  • Cell migration
  • Endothelial-cell behavior
  • Angiogenesis
  • Tissue remodeling
  • Extracellular matrix dynamics

For the isolated TB-500 fragment specifically, comprehensive human pharmacodynamic characterization remains limited.

Pharmacokinetic Profile

A definitive human pharmacokinetic profile for the isolated TB-500 fragment has not been comprehensively established.

Available information does not support assigning a definitive human half-life, bioavailability, clearance rate, or tissue-distribution profile to TB-500 without specifying the exact molecular form and route of administration.

Parameter Research Profile
Molecular Type Synthetic heptapeptide
Sequence Ac-LKKTETQ
Molecular Weight ~889 Da
Primary Biological Domain Actin/cytoskeletal biology
Human PK Characterization Limited
Human PD Characterization Limited
Metabolic Fate Under investigation

RESEARCH HIGHLIGHTS

Actin-Associated Biology

The LKKTETQ region represents a key actin-binding motif within Thymosin Beta-4. Experimental research has connected this region with actin-dependent cellular processes.

Cellular Migration

Tβ4 research has demonstrated effects on endothelial-cell migration, an important component of angiogenesis and tissue remodeling.

Angiogenesis

The actin-binding region of Tβ4 has been investigated in endothelial migration and vessel-sprouting models, providing mechanistic interest in vascular remodeling research.

Tissue Remodeling

Thymosin Beta-4 research encompasses cellular migration, extracellular matrix interactions and tissue-remodeling processes, making the Tβ4/TB-500 family relevant to regenerative biology research.

Analytical Identity

Because TB-500 is used inconsistently to describe both the fragment and full-length Tβ4, mass spectrometry and lot-specific molecular characterization are particularly important when establishing product identity.


TECHNICAL SPECIFICATIONS

Specification PharmaTech Standard
Product Name TB-500
Molecular Form N-acetylated Tβ4 fragment
Peptide Length 7 amino acids
Sequence Ac-LKKTETQ
Molecular Formula C₃₈H₆₈N₁₀O₁₄
Molecular Weight ~889.0 Da
CAS 885340-08-9
Appearance White to off-white lyophilized powder
Identity Testing Mass Spectrometry
Purity Testing HPLC
Sequence Verification MS/MS / analytical characterization
Packaging PharmaTech specification
Lot Number PharmaTech lot-specific
Certificate of Analysis Available by lot

STORAGE & HANDLING

TB-500 should be maintained in its lyophilized form under controlled storage conditions and protected from:

  • Excessive heat
  • Moisture
  • Direct light
  • Repeated temperature fluctuations

PharmaTech lot-specific storage and handling specifications should be followed according to the corresponding product documentation and Certificate of Analysis.